-
Reducing bleeding, protecting joints, and medication safety, the evidence is here!
Time of Update: 2021-10-01
To summarize a number of clinical studies and real-world studies, patients with childhood hemophilia A receiving rAHF-PFM preventive treatment can reduce bleeding, delay the occurrence of joint damage, improve joint health outcomes, and have better safety .
-
Consolidate the value of radiotherapy in the first-line treatment of DLBCL patients
Time of Update: 2021-10-01
03 Study Conclusions This large comprehensive meta-analysis conducted by the investigators contains the best currently available data from randomized trials of consolidation radiotherapy in the first-line treatment of aggressive lymphoma .
-
CCSC: Go ahead and promote CAR-T in the treatment of blood diseases at home and abroad
Time of Update: 2021-10-01
Neelapu from the University of Texas Anderson Cancer Medical Center was invited to interpret CAR-T international clinical Application; and Professor Mei Heng from Union Hospital of Huazhong University of Science and Technology shared the Kirin collection: an introduction to CAR-T research in Wuhan Union Hospital; focusing on the progress and management of CAR-T at home and abroad, together bringing us an academic gluttonous feast .
-
The goal of treatment changes, and there is no limit to pursuing TFR-so that every CML patient has at least one opportunity to pursue TFR
Time of Update: 2021-10-01
Since the pioneer trial STIM1, a number of clinical trials have evaluated the feasibility of stopping TKI treatment (close monitoring) in patients who have been strictly selected and have achieved and maintained DMR for more than 2 years [6] .
-
Cancer Discovery Jianping Li reveals a new mechanism of glucocorticoid resistance in leukemia
Time of Update: 2021-10-01
Researchers use CRISPR/Cas9 to edit ALL cell lines, NOD SCID, and leukemia patient-derived xenograft tumors (PDX) and other models, applying a large number of drug screening and appearance Multi-omics analysis of genetic regulation revealed a new mechanism of glucocorticoid resistance in children with acute lymphoblastic leukemia with NSD2 gene mutations, and found a new strategy for reversing glucocorticoid resistance based on this .
-
2021 IMW Expert Interview｜Professor Chen Wenming: Domestic CPT shows promising treatment prospects in RRMM
Time of Update: 2021-10-01
At this conference, a CPT (recombinant allosteric human tumor necrosis factor-related apoptosis-inducing ligand) combined with thalidomide and dexamethasone in the treatment of relapsed and refractory multiple myeloma (RRMM) by the team of Professor Chen Wenming Selected for poster presentation .
-
Professor Han Weidong interviewed to quell CRS, tocilizumab escorted CAR-T precision treatment
Time of Update: 2021-10-01
CRS: CAR-T cells specifically recognize tumor-associated antigen targets after reinfusion into the patient's body, and the recognition and binding triggers the activation of CAR-T cells, and induces a large number of inflammatory cytokines such as interleukin 1 (IL-1) and IL-2 , IL-6 and tumor necrosis factor (TNF) release .
-
2021 SOHO Expert Interview｜Professor Jing Hongmei talks about the progress and prospects of MCL treatment
Time of Update: 2021-10-01
The team of Professor Jing Hongmei from Peking University Third Hospital conducted a study to explore the role of cell division cyclin 20 (CDC20) in MCL.
-
2021 SOHO Burkitt's lymphoma modern prognostic model and treatment model
Time of Update: 2021-10-01
It is worth noting that the low-risk BL patients in the study did not receive preventive treatment for the CNS, and the EFS rate reached 100% after 3 treatment cycles.
-
915 million era special: standardized full-process management, lymphoma is expected to be cured
Time of Update: 2021-10-01
" On this occasion, this issue of "Big Coffee Yiqi" invited Professor Yang Shenmiao from the Institute of Hematology, Peking University as a visitor, and also invited Shi Yuankai, Dean of Tumor Hospital of Chinese Academy of Medical Sciences, and Professor Jing Hongmei of Peking University Third Hospital as interview guests, discussed in-depth "Standardized Full-Process Management of Lymphoma Patients" .
-
CCSC: China Foreign Exchange, CAR-T's new idea in the treatment of blood diseases——Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Time of Update: 2021-10-01
Professor Cao Yang mainly introduced a study of his team on continuous infusion of anti-CD19 and anti-CD22 CAR-T therapy for patients with relapsed and refractory high-risk B-cell lymphoma after transplantation .
-
2021 IMW Big Coffee Commentary｜Professor Liu Aijun's interpretation of the Phase I study of elranatamab in the treatment of RRMM
Time of Update: 2021-10-01
MagnetisMM-1 study (NCT03269136) is a phase I clinical study aimed at exploring the efficacy, safety, and pharmacokinetics of elranatamab and its combined immunomodulators in the treatment of patients with relapsed and refractory multiple myeloma (RRMM) And pharmacodynamics .
-
Express one-time gene therapy takes an important step to treat beta thalassemia
Time of Update: 2021-10-01
▎The content team editor of WuXi AppTec today, bluebird bio announced that it has completed the submission of a rolling biologics license application (BLA) for gene therapy betibeglogene autotemcel (beti-cel) to the US FDA .
-
Express JAK inhibitor obtains FDA approval again to treat fatal complications of stem cell transplantation
Time of Update: 2021-09-30
▎The content team editor of WuXi AppTec today, Incyte announced that the US FDA has approved its JAK inhibitor Jakafi (ruxolitinib) for extended indications for the treatment of chronic graft-versus-host disease (GVHD) adults and over 12 years old Child patient .
-
FDA renews approval of Rucotinib for the treatment of chronic graft-versus-host disease
Time of Update: 2021-09-30
The median time from the first remission to death or the start of new cGVHD systemic treatment for patients in the Rucotinib and BAT groups was 25 months (95% CI: 16.
-
LEUKEMIA: Circulating cytokines in patients with multiple myeloma inhibit osteoblast differentiation of adipose stem cells
Time of Update: 2021-09-29
90% of patients have osteolysis-related bone pain and spontaneous fractures as their main symptoms, but they may also be related to anemia, renal failure, hypercalcemia, spinal cord compression, and immunodeficiency .
-
LEUKEMIA: Complete diagnostic criteria for bone marrow mastocytosis-Proposal of the European Mastocytosis Competence Network
Time of Update: 2021-09-29
diagnosisForeign research teams have conducted a deeper understanding of the poor prognostic factors of WHO-based BMM patients in the ECNM registry data set, and compared whether BMM has these risk factors and the characteristics and characteristics of typical ISM with skin lesions (ISMtyp).
-
AMERICAN JOURNAL OF HEMATOLOGY: Eosinophilic disease as defined by the World Health Organization: Diagnosis, risk stratification and management update in 2021.
Time of Update: 2021-09-29
Eosinophilia includes a wide range of non-hematological (secondary or reactive) and hematological (primary or clonal) diseases, and may lead to end-organ damage .
This includes the main category "myeloid/lymphoid tumors with eosinophilia and PDGFRA, PDGFRB or FGFR1 or PCM1-JAK2 rearrangement", and the MPN subtype "chronic eosinophilic leukemia, not otherwise specified" (CEL , NOS) .
-
Haematologica: In vitro and in vivo multicolor report on the morphological dynamics of single platelets and megakaryocytes revealed by mouse strains
Time of Update: 2021-09-29
Single platelet and megakaryocyte morpho-dynamics uncovered by multicolor reporter mouse strains in vitro and in vivoNicolai L, Kaiser R, Escaig R, Hoffknecht ML, Anjum A, Leunig A, Pircher J, Ehrlich A, Lorenz M, Ishikawa-Ankerhold H, Aird WC, Massberg S, Gaertner F.
-
BLOOD: PKM2 promotes neutrophil activation and cerebral thrombotic inflammation in the treatment of ischemic stroke
Time of Update: 2021-09-29
Thrombotic strokeRecently, a research team found that in humans and mice, after an ischemic stroke, the nuclear pyruvate kinase muscle 2 (PKM2) in neutrophils is a modulator of systemic inflammation.
PKM2 promotes neutrophil activation and cerebral thrombo-inflammation: Therapeutic implications for ischemic stroke Blood Blood 2021; blood.
